Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

56
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

83
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
83
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

40
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
40
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

50
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
50

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology." Kidney International, 2023;104:36-45.

Kidney international·2023
Same author

[IgA nephropathy].

Innere Medizin (Heidelberg, Germany)·2023
Same author

Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2023
Same author

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.

Lancet (London, England)·2023
Same author

Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023

Related Experiment Video

Updated: Sep 6, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K

Assessing prognosis in IgA nephropathy.

Jürgen Floege1, Stephanie Wied2, Thomas Rauen1

  • 1Division of Nephrology and Immunology, Rheinisch Westfälische Technische Hochschule University of Aachen, Aachen, Germany.

Kidney International
|June 23, 2022
PubMed
Summary

Prognosis assessment in IgA nephropathy is crucial. A new prediction tool improves upon the KDIGO guidelines by offering prognosis predictions 1-2 years post-biopsy, addressing a key limitation of the previous version.

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.9K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

765

Related Experiment Videos

Last Updated: Sep 6, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.9K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

765

Area of Science:

  • Nephrology
  • Clinical Epidemiology
  • Biostatistics

Background:

  • Prognosis assessment is vital for managing chronic kidney diseases like IgA nephropathy.
  • Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest the "International IgAN Prediction Tool" for prognosis.
  • The existing tool's limitation is its validation solely at the time of kidney biopsy.

Purpose of the Study:

  • To introduce and review an improved algorithm for IgA nephropathy prognosis.
  • To address the limitation of the "International IgAN Prediction Tool" by enabling predictions at 1-2 years post-biopsy.
  • To evaluate the strengths, limitations, and clinical utility of this enhanced prediction tool.

Main Methods:

  • Development of a new prediction algorithm for IgA nephropathy.
  • Validation of the algorithm for predicting prognosis at 1 and 2 years after kidney biopsy.
  • Review of the algorithm's performance, including its strengths and weaknesses.

Main Results:

  • An improved algorithm allows for prognosis assessment at 1 and 2 years post-kidney biopsy.
  • This new tool overcomes the temporal limitation of the previous "International IgAN Prediction Tool".
  • The review discusses the clinical applicability and potential impact of the enhanced tool.

Conclusions:

  • The enhanced prediction tool offers a more dynamic approach to assessing IgA nephropathy prognosis.
  • It provides valuable prognostic information beyond the immediate post-biopsy period.
  • The tool holds potential for improved clinical decision-making and patient management in IgA nephropathy.